Exhaled breath condensate - a new tool for assessment of idiopathic pulmonary fibrosis?

Przysucha, Natalia; Górska, Katarzyna; Paplińska, Magdalena; Nejman-Gryz, Patrycja; Proboszcz, Magdalena; Krenke, Rafał

doi:10.1183/13993003.congress-2018.pa2931

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the selection of the cytokines (IL-6, IL-8, IL-15, TNF-α and VEGF-A) was based on our previous pilot study involving patients with IPF in which the EBC cytokine profile was assessed on the Luminex platform. Not only did we show that detectable concentrations of these five cytokines were present in EBC, but we also found some significant correlations between cytokine levels and IPF clinical indices in that study [24].…”

Section: Discussionsupporting

confidence: 70%

“…The selection of the investigated cytokines was based on our previous pilot study performed in patients with IPF in which the expression of the following cytokines was assessed on the multiplex bead-based cytokine assay: IL-1β, -1Ra, -5, -6, -8, -10, -15, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-gamma (IFNγ), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein 1 alpha (MIP-1α) and beta (MIP-1β), platelet-derived growth factor-beta (PDGF-β), TNFα, VEGF [24]. Of these, only five (IL-6, IL-8, IL-15, TNFα and VEGF) reached concentrations above the detection levels and were therefore selected for the current analysis.…”

Section: Cytokine Measurements In Ebcmentioning

confidence: 99%

See 1 more Smart Citation

Exhaled Biomarkers in Idiopathic Pulmonary Fibrosis—A Six-Month Follow-up Study in Patients Treated with Pirfenidone

Jaśkiewicz

Mycroft

Maskey-Warzęchowska

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

The mechanism of action of pirfenidone in idiopathic pulmonary fibrosis (IPF) has not been fully elucidated. To offer additional insight, we evaluated the change in the cytokine profile in exhaled breath condensate (EBC) following a six-month treatment with pirfenidone in patients with IPF. EBC concentrations of interleukin (IL)-6, IL-8, IL-15, TNF-α and VEGF-A were assessed with ELISA and compared at baseline and after six months of pirfenidone treatment. Twenty-nine patients with IPF and 13 controls were evaluated at baseline. With the exception of IL-8 concentration, which was lower in patients with IPF when compared to controls (p = 0.005), the cytokine levels did not differ between the groups. Despite the use of a high sensitivity assay, IL-8 reached detectable values only in 24% of IPF patients. EBC analysis after six months of treatment with pirfenidone did not reveal any differences in the cytokine levels. The change in EBC vascular endothelial growth factor A (VEGF-A) correlated with the change in the 6 min walk distance (r = 0.54, p = 0.045). We conclude that a six-month treatment with pirfenidone did not significantly change the EBC cytokine profile. Our findings support the potential usefulness of VEGF-A as a marker in IPF. The low EBC IL-8 level in patients with IPF is a novel finding which needs confirmation in larger studies.

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Cytokine Measurements In Ebcmentioning

confidence: 99%